(Q35690135)

9 August 2017

Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol (English)

1 reference

9 August 2017

1 reference

meglumine antimoniate

1 reference

1 reference

6

Angelo Elio Gravino

1 reference

9 August 2017

1

Laura Manna

1 reference

9 August 2017

Raffaele Corso

2

1 reference

9 August 2017

Giorgio Galiero

series ordinal

3

1 reference

9 August 2017

Anna Cerrone

series ordinal

4

1 reference

9 August 2017

Paolo Muzj

series ordinal

5

1 reference

9 August 2017

28 May 2015

1 reference

9 August 2017

Parasites and Vectors

1 reference

9 August 2017

8

1 reference

9 August 2017

289

1 reference

Creative Commons Attribution 4.0 International

9 August 2017

start time

28 May 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s13071-015-0896-0

0 references

cites work

Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Canine leishmaniosis--new concepts and insights on an expanding zoonosis: part two.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Quality control methods in sero-immunologic tests for infectious diseases

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

[Cutaneous adverse drug reactions].

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Ethical and epidemiological dilemmas in the treatment of dogs for visceral leishmaniasis in Latin America

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Meglumine antimonate directly increases phagocytosis, superoxide anion and TNF-alpha production, but only via TNF-alpha it indirectly increases nitric oxide production by phagocytes of healthy individuals, in vitro.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Leishmania DNA load and cytokine expression levels in asymptomatic naturally infected dogs.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Detailed analysis of an experimental challenge model for Leishmania infantum (JPC strain) in dogs

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4458061

Serological diagnosis and treatment of canine leishmaniasis

25 September 2018

1 reference

12 December 2020

Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases)

1 reference

12 December 2020

Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis

1 reference

12 December 2020

Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol

1 reference

12 December 2020

Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol

1 reference

12 December 2020

Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use

1 reference

12 December 2020

Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction

1 reference

12 December 2020

10.1186/S13071-015-0896-0

Identifiers

DOI

1 reference

Dimensions Publication ID

9 August 2017

0 references

1 reference

9 August 2017

1 reference